New Genetic Markers for Prostate Cancer

Prostate cancer risk stratification based on conventional clinical and pathologic characteristics alone may misclassify a proportion of men at various stages of the disease process. Many gene-based assays have emerged in recent years that seek to improve the predictive accuracy in the prediagnostic...

Full description

Saved in:

Bibliographic Details
Published in:	Urologic clinics of North America Vol. 43; no. 1; pp. 7 - 15
Main Authors:	Leapman, Michael S., MD, Carroll, Peter R., MD, MPH
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-02-2016
Subjects:	Biomarker Biomarkers, Tumor - genetics Disease Progression Gene Expression Regulation, Neoplastic Gene expression testing Genetic Markers Humans Male Predictive Value of Tests Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - genetics Prostatic Neoplasms - therapy Risk Assessment Urology Gene expression testing Prostate cancer Biomarker
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Prostate cancer risk stratification based on conventional clinical and pathologic characteristics alone may misclassify a proportion of men at various stages of the disease process. Many gene-based assays have emerged in recent years that seek to improve the predictive accuracy in the prediagnostic and postdiagnostic settings. Following primary treatment failure, gene expression tests may offer improved stratification of individuals at risk for disease progression and inform refinements in the necessity of additional treatment. Unifying limitations among all novel gene-based tests are include clinical validation derived from historical cohorts and a dearth of empirical clinical effectiveness data.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0094-0143 1558-318X
DOI:	10.1016/j.ucl.2015.08.002